Decitabine/Cedazuridine as Maintenance Therapy
A Phase Ib Study of Oral Decitabine/Cedazuridine as Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Patients With Myeloid Neoplasms
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 22 patients (estimated)
- Sponsors
- Massachusetts General Hospital
- Collaborators
- Taiho Oncology, Inc.
- Tags
- Chemotherapy, Cytidine Deaminase Inhibitor (CDAi), Hypomethylating Agents (HMA), Nucleoside Metabolic Inhibitor, Maintenance, Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1559
- NCT Identifier
- NCT04980404
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.